CGT

7개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved7 programs
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 2

Anti-CD7 CAR-T (Anti-CD7 CAR-T)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

C9/CD5CAR/IL-15 NK cells (C9/CD5CAR/IL-15 NK cells)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleChang YingjunPhase 2

CD19-BCMA dual nanobody based CAR-T Cells (CD19-BCMA dual nanobody based CAR-T Cells)

Transplantation Candidates With Hematological Diseases · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 1

CD20/CD22 dual Targeted CAR T-cells (CD20/CD22 dual Targeted CAR T-cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 2

GC022F CAR-T cells (GC022F CAR-T cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleLakefront Biotherapeutics NVPhase 3

GLPG CAR T-cell therapy (GLPG CAR T-cell therapy)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting